GTL001, a therapeutic vaccine for women infected with human papillomavirus 16 or 18 and normal cervical cytology: Results of a phase I clinical trial

Clinical Cancer Research

Volumn 22, Issue 13, 2016, Pages 3238-3248

  Van Damme, Pierre ^a   Bouillette Marussig, Myriam ^b   Hens, Annick ^a   De Coster, Ilse ^a   Depuydt, Christophe ^c   Goubier, Anne ^d   Van Tendeloo, Viggo ^a   Cools, Nathalie ^a   Goossens, Herman ^a   Hercend, Thierry ^e   Timmerman, Benedikt ^f   Bissery, Marie Christine ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Genticel   (France)

^c AML   (Belgium)

^d Tusk Therapeutics   (Belgium)

^e Edmond de Rothschild Investment Partners   (France)

^f Genticel SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GTL 001; IMIQUIMOD; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE; AMINOQUINOLINE DERIVATIVE; DNA BINDING PROTEIN; E7 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOLOGICAL ADJUVANT; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; WART VIRUS VACCINE;

ADULT; ADVERSE OUTCOME; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GYNECOLOGICAL EXAMINATION; HEADACHE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; INJECTION SITE ULCER; MIDDLE AGED; MYALGIA; OPEN STUDY; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; UTERINE CERVIX CYTOLOGY; VIRAL CLEARANCE; VIRUS LOAD; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; UTERINE CERVIX; UTERINE CERVIX TUMOR; VACCINATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AMINOQUINOLINES; CERVIX UTERI; DNA-BINDING PROTEINS; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL LOAD; YOUNG ADULT;

EID: 84977111414     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0085     Document Type: Article

References (37)

1. Kitchener HC, Denton K, Soldan K, Crosbie EJ. Developing role of HPV in cervical cancer prevention. Br Med J 2013;347:f4781.
2. Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, et al. Therapy of human papillomavirus-related disease. Vaccine 2012;30Suppl 5:F71-82.
3. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489-98.
4. Vrzackova P, Weiss P, Cibula D. Sexual morbidity following radical hysterectomy for cervical cancer. Expert Rev Anticancer Ther 2010;10:1037-42.
5. Wit EM, Horenblas S. Urological complications after treatment of cervical cancer. Nat Rev Urol 2014;11:110-7.
6. van der Burg SH, Melief CJ. Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol 2011;23:252-7.
7. Brun JL, Dalstein V, Leveque J, Mathevet P, Raulic P, Baldauf JJ, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 2011;204:169e1-8.
8. Kawana K, Adachi K, Kojima S, Kozuma S, Fujii T. Therapeutic human papillomavirus (HPV) vaccines: a novel approach. Open Virol J 2012;6:264-9.
9. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines-immune responses. Vaccine 2012;30Suppl 5:F83-7.
10. Morrow MP, Yan J, Sardesai NY. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines 2013;12:271-83.
11. Khallouf H, Grabowska AK, Riemer AB. Therapeutic vaccine strategies against human papillomavirus. Vaccines 2014;2:422-62.
12. Tran NP, Hung CF, Roden R, Wu TC. Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res 2014;193:149-71.
13. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015;386:2078-88.
14. Alvarez RD, Huh WK, Bae S, Lamb LSJr., Conner MG, Boyer J, et al. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecol Oncol 2016;140:245-52.
15. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet 2013;382:889-99.
16. Simsova M, Sebo P, Leclerc C. The adenylate cyclase toxin from Bordetella pertussis-a novel promising vehicle for antigen delivery to dendritic cells. Int J Med Microbiol 2004;293:571-6.
17. Preville X, Ladant D, Timmerman B, Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005;65:641-9.
18. Berraondo P, Nouze C, Preville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007;67:8847-55.
19. Esquerré M, Bouillette-Marussig M, Goubier A, Momot M, Keller H, Bissery M. Preclinical results of ProCervix, a first in class, first in indication therapeutic vaccine targeting HPV16/18 infected women. Eur J Cancer 2014;50(Suppl 6):45.
20. Food and Drug Administration Center for Biologics Evaluation and Research. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Rockville, MD: US Food and Drug Administration; 2007.
21. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
22. Micalessi IM, Boulet GA, Bogers JJ, Benoy IH, Depuydt CE. High-throughput detection, genotypingand quantification of the human papillomavirus using real-time PCR. Clin Chem Lab Med 2012;50:655-61.
23. Depuydt CE, Benoy IH, Beert JF, Criel AM, Bogers JJ, Arbyn M. Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening. J Clin Microbiol 2012;50:4073-7.
24. Gmira S, Karimova G, Ladant D. Characterization of recombinant Bordetella pertussis adenylate cyclase toxins carrying passenger proteins. Res Microbiol 2001;152:889-900.
25. Mirecka EA, Rudolph R, Hey T. Expression and purification of His-tagged HPV16 E7 protein active in pRb binding. Protein Exp Purif 2006;48:281-91.
26. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16.
27. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008;48:1267-81.
28. Fritsche PJ, Helbling A, Ballmer-Weber BK. Vaccine hypersensitivity-update and overview. Swiss Med Wkly 2010;140:238-46.
29. Hwang S-A, Actor JK. Hypersensitivity: T Lymphocyte Mediated (Type IV). In: eLS. Chichester: John Wiley & Sons Ltd; 2015. p. 1-8.
30. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010;107:11895-9.
31. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer 2009;19:508-12.
32. Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol 2007;157Suppl 2:8-13.
33. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008;181:776-84.
34. Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007;121:2794-800.
35. Roman LD, Wilczynski S, Muderspach LI, Burnett AF, O'Meara A, Brinkman JA, et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007;106:558-66.
36. Rosales R, Lopez-Contreras M, Magallanes JR, Gonzalez-Vergara R, Arroyo-Cazarez JM, Ricardez-Arenas A, et al. Regression of HPV intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther 2014;25:1035-49.
37. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-7.